Tau spreading refers to the progressive intercellular transmission of pathologically misfolded tau protein in Alzheimer's disease and related tauopathies[1][2]. This mechanism underlies the stereotypical pattern of neurofibrillary tangle deposition described by Braak staging and represents a key therapeutic target for disease modification. The prion-like propagation of tau represents one of the most significant discoveries in neurodegenerative disease research in recent decades, fundamentally shifting our understanding of how protein misfolding disorders progress through the brain[3][4].
The concept of tau spreading emerged from groundbreaking experiments demonstrating that pathological tau aggregates could be transmitted from affected to unaffected neurons, propagating pathology along connected neural circuits[5]. This observation provided a mechanistic explanation for the predictable staging of tau pathology observed in postmortem brain studies and opened new avenues for understanding disease progression and therapeutic intervention[6].
Tau is a microtubule-associated protein encoded by the MAPT gene[7] that plays essential roles in neuronal physiology:
Microtubule stabilization: Tau binds to microtubules through its repeat domains, promoting polymerization and preventing depolymerization. This function is critical for maintaining axonal integrity and axonal transport efficiency[8].
Axonal transport modulation: Through its interaction with motor proteins including kinesin and dynein, tau regulates the bidirectional movement of vesicles, organelles, and signaling complexes along axons[9].
Synaptic function support: Tau localizes to synapses where it modulates synaptic vesicle trafficking, neurotransmitter release, and postsynaptic receptor density[10].
Neuronal viability: Tau participates in cellular signaling pathways that support neuronal survival, including interactions with the PI3K-Akt signaling pathway[11].
The tau protein exists as six isoforms in the human brain, generated by alternative splicing of exon 2, exon 3, and exon 10. These isoforms differ in the number of repeat domains (3R or 4R) and N-terminal inserts, with 3R and 4R isoforms playing distinct roles in different tauopathies[12].
Under disease conditions, tau undergoes a series of transformative changes that convert a normally functional protein into a toxic aggregate[13][14]:
Hyperphosphorylation: Abnormal POST-translational modification, particularly at sites including Ser202, Thr205, Ser396, and Ser404, reduces tau's affinity for microtubules and promotes its aggregation[15].
Oligomerization: Soluble toxic oligomers form as intermediate species during the aggregation process. These oligomers are increasingly recognized as the most neurotoxic species, more damaging than mature fibrils[16].
Fibrillization: Pathological tau assembles into paired helical filaments (PHFs) and straight filaments (SFs), the structural components of neurofibrillary tangles[17].
Aggregation: Hyperphosphorylated tau and PHFs deposit as insoluble neurofibrillary tangles (NFTs), which can persist for years and serve as a reservoir of pathological material[18].
The conversion from normal tau to pathological aggregates involves a conformational change from a disordered, soluble protein to a β-sheet-rich, aggregation-prone structure. This conformational shift is central to the templating capability that underlies prion-like propagation[19].
Tau propagation follows prion-like principles wherein pathological conformers can induce conformational changes in normal tau molecules, perpetuating the aggregation cycle[20][21]:
| Step | Process | Molecular Mechanisms |
|---|---|---|
| Release | Tau seeds exit cells via extracellular vesicles, synaptic activity, or direct membrane translocation | Exosome release[22], activity-dependent secretion[23], unconventional secretion pathways[24] |
| Uptake | Neighboring neurons internalize via endocytosis, receptor-mediated uptake | Heparan sulfate proteoglycan-mediated endocytosis[25], Fc receptor involvement[26] |
| Templation | Native tau converts to pathological conformation | Seeding by oligomeric/fibrillar templates[27], strain-specific conformations[28] |
| Spread | Propagation along neuronal circuits | Anterograde and retrograde axonal transport[29], transsynaptic spread[30] |
The release of tau into the extracellular space occurs through multiple mechanisms. Synaptic activity represents a major driver of tau secretion, with neuronal excitation leading to increased tau release[31]. This activity-dependent release explains why functionally connected neurons show synchronized pathology propagation[32].
Different tau conformers (strains) determine distinct pathological and clinical phenotypes[33][34]. The concept of strain diversity in tauopathies mirrors prion strain biology, where identical primary sequences can adopt multiple distinct conformations with different biological properties[35]:
Strain identity is encoded in the detailed structure of tau filaments, which can be distinguished by cryo-electron microscopy[40]. These structural differences have profound implications for disease classification, biomarker development, and therapeutic targeting[41].
The progression of tau pathology follows the predictable Braak stages, reflecting the spread of pathology along connected neural networks[42][43]:
| Stage | Region Affected | Clinical Correlation | Pathology Extent |
|---|---|---|---|
| 0 | None | Normal aging | No detectable pathology |
| I-II | Transentorhinal cortex, entorhinal cortex | Preclinical, subjective cognitive decline | Limited to entorhinal region |
| III-IV | Limbic system (hippocampus, amygdala) | Mild cognitive impairment, early AD | Limbic system involvement |
| V-VI | Isocortical regions | Moderate to severe AD | Global cortical involvement |
The Braak staging system, developed by Heiko and Eva Braak in 1991, remains one of the most robust neuropathological correlates of cognitive impairment in Alzheimer's disease[44]. The tight correlation between NFT burden and cognitive status underscores the central role of tau pathology in mediating neurodegeneration and clinical decline[45].
Tau spreads along connected neural networks through multiple mechanisms[46][47]:
Synaptic transmission: Synaptic connections provide direct pathways for tau propagation. Pathological tau can be released from presynaptic terminals and taken up by postsynaptic neurons, enabling transsynaptic spread[48]. This mechanism explains the characteristic pattern of pathology progression along functionally connected brain regions[49].
Axonal transport: Both anterograde and retrograde axonal transport mechanisms facilitate the movement of pathological tau species between neuronal compartments. The microtubule-based motor proteins kinesin and dynein mediate this transport, which can carry tau-containing vesicles bidirectionally along axons[50].
Network activity effects: Functionally connected neurons show correlated patterns of tau pathology progression[51]. Studies using functional connectivity mapping have demonstrated that regions with strong metabolic coupling exhibit synchronized tau accumulation, supporting the network-based spread model[52].
Vulnerability factors: Certain neuronal populations demonstrate heightened susceptibility to tau propagation. Large, highly connected neurons in Layer II of the entorhinal cortex represent early targets in Alzheimer's disease, likely due to their extensive connectivity and high metabolic demand[53].
Glia participate significantly in tau clearance and spread[54][55]:
Astrocytes: Astrocytes may internalize extracellular tau through endocytosis and can potentially transfer tau to other cells[56]. In tauopathies, astrocytes develop characteristic tau pathology (ARTAG, Tauopathy Astrocytes) that contributes to disease progression[57]. Astrocytic tau pathology may represent both a clearance mechanism gone awry and an active contributor to propagation[58].
Microglia: As the brain's primary immune cells, microglia mediate tau clearance but can also inadvertently spread tau through exosome release[59]. Microglial activation states influence tau pathology progression, with chronic neuroinflammation promoting propagation while acute activation may facilitate clearance[60].
Oligodendrocytes: In certain tauopathies including progressive supranuclear palsy and corticobasal degeneration, oligodendrocytes contain tau pathology that may contribute to white matter degeneration[61]. The role of oligodendrocytes in tau propagation remains an active area of investigation[62].
Extracellular vesicles: Exosomes and other extracellular vesicles serve as vehicles for tau release and cell-to-cell transfer[63]. These vesicles can contain both monomeric and aggregated tau species, with exosome-associated tau showing enhanced seeding activity[64].
Neuronal activity profoundly influences tau secretion rates[65][66]:
Synaptic transmission: Action potential firing stimulates tau release from presynaptic terminals[67]. Glutamatergic signaling, particularly through NMDA receptors, enhances tau secretion through calcium-dependent mechanisms[68].
Excitotoxicity: Excessive neuronal excitation leads to increased tau release and propagation[69]. This finding links the well-established role of excitotoxicity in Alzheimer's disease to tau spreading mechanisms[70].
Network oscillations: High-frequency oscillations, particularly gamma frequency activity, have been associated with enhanced tau pathology propagation[71]. Sleep disruption, which alters neural network activity patterns, may therefore influence tau spreading kinetics[72].
Multiple vesicular pathways contribute to tau secretion[73][74]:
Exosomes: Tau is packaged into exosomes through the endosomal pathway, with intraluminal vesicles containing tau species released upon exosome fusion with the plasma membrane[75]. Exosomal tau demonstrates enhanced biological activity in seeding assays compared to free tau[76].
Synaptic vesicles: Tau localizes to synaptic vesicles and can be released through synaptic vesicle exocytosis[77]. This pathway provides a direct mechanism linking synaptic activity to tau propagation[78].
Direct membrane translocation: Tau can exit cells through direct translocation across the plasma membrane, a process that may be enhanced under cellular stress conditions[79].
Brain functional connectivity strongly predicts tau propagation patterns[80][81]:
Default mode network: The default mode network, active during rest and memory consolidation, shows particular vulnerability to tau accumulation[82]. This network's involvement explains why memory systems are affected early in Alzheimer's disease[83].
Structural connectivity: White matter tract integrity correlates with tau spread rates, supporting the hypothesis that anatomical connections provide pathways for propagation[84].
Metabolic coupling: Regions with high metabolic demand and correlated activity show synchronized tau accumulation[85].
Therapeutic approaches targeting neuronal activity may influence tau propagation[86][87]:
Anti-epileptic treatments: Given the increased seizure activity in some Alzheimer's disease patients, anti-epileptic drugs have been investigated for their potential to reduce tau propagation[88].
Brain stimulation: Both invasive and non-invasive brain stimulation approaches may modulate network activity in ways that influence tau spreading[89].
Lifestyle interventions: Exercise and cognitive activity, which alter network activity patterns, have been associated with reduced tau accumulation in clinical studies[90].
Tau propagation is modulated by genetic and environmental factors[91][92]:
MAPT haplotype: The MAPT H1 haplotype is associated with increased risk for progressive supranuclear palsy and corticobasal degeneration, while H2 haplotype shows different regional patterns of vulnerability[93][94].
APOE genotype: The APOE ε4 allele accelerates tau propagation, likely through effects on tau clearance, neuroinflammation, and neuronal activity[95]. APOE ε4 carriers show earlier onset and more rapid progression of tau pathology[96].
Traumatic brain injury: Moderate to severe traumatic brain injury increases long-term risk for chronic traumatic encephalopathy and accelerates tau pathology in animal models[97].
Neuroinflammation: Chronic neuroinflammation creates a permissive environment for tau propagation through effects on glial function and blood-brain barrier integrity[98].
Several factors may modify tau spreading kinetics[99][100]:
Exercise: Regular physical exercise is associated with reduced tau accumulation in humans and mice, potentially through enhanced glymphatic clearance and neuroplasticity mechanisms[101][102].
Cognitive reserve: Higher education and cognitive engagement are associated with slower tau progression, possibly through increased synaptic resilience and network redundancy[103].
Sleep quality: Adequate sleep, particularly slow-wave sleep, supports glymphatic clearance of tau and may reduce propagation[104].
Multiple disease-modifying strategies targeting tau spreading are under development[105][106]:
Active immunization: Vaccines targeting tau aim to generate antibodies that neutralize extracellular tau and prevent neuronal uptake. Several candidates have entered clinical trials[107].
Passive immunization: Monoclonal antibodies against tau are designed to bind pathological tau species in the extracellular space and facilitate clearance. LAMP1A and others have shown promise in preclinical studies[108].
Small molecule inhibitors: Compounds targeting tau aggregation (e.g., methylene blue derivatives, bryostatin analogs) aim to prevent the conformational conversion that enables templated propagation[109].
Oligomer modulators: Agents targeting toxic oligomers rather than mature fibrils may prevent the most damaging species from seeding new aggregates[110].
Tau phosphorylation modulators: Kinase inhibitors and phosphatase activators that reduce tau phosphorylation could prevent the initial steps in pathological conversion[111].
Gene therapy: Approaches using antisense oligonucleotides or viral vectors to reduce MAPT expression represent long-term strategies for disease modification[112].
Tau-targeted therapies span multiple clinical trial phases[113][114]:
| Agent | Mechanism | Phase | Status |
|---|---|---|---|
| AADvac1 | Active immunization | Phase 2 | Completed |
| ACI-35 | Active immunization (phospho-tau) | Phase 1/2 | Completed |
| LMTM (TRx0237) | Tau aggregation inhibitor | Phase 3 | Completed |
| Bepranemab | Anti-tau antibody | Phase 2 | Ongoing |
| Semorinemab | Anti-tau antibody | Phase 2 | Completed |
| Tilavonemab | Anti-tau antibody (N-terminal) | Phase 2 | Failed |
| E2814 (Etalanetug) | Anti-tau antibody (MTBR) | Phase 2 | Ongoing |
E2814 (etanlanetug) represents the most advanced anti-tau antibody in development, targeting the microtubule-binding region (MTBR) of tau rather than the N-terminal region targeted by earlier antibodies. This fundamental difference in epitope selection addresses key limitations of previous approaches:
The MTBR-targeting approach directly addresses the mechanism of tau spreading by:
The tilavonemab (ABBV-8E12) Phase 2 trial in PSP failed to meet primary efficacy endpoints, providing critical lessons for the anti-tau field (see Tilavonemab PSP Trial):
This failure led to the shift toward MTBR-targeting antibodies like E2814 that can directly engage the aggregation-prone region.
Tau propagation markers enable disease monitoring and therapeutic response assessment[115][116]:
Tau PET using flortaucipir (FTP, AV-1451) provides direct visualization of tau pathology distribution in vivo:
Cerebrospinal fluid biomarkers provide insights into tau pathology dynamics:
| Biomarker | Interpretation | Clinical Correlation |
|---|---|---|
| p-tau181 | Phosphorylated tau release | Correlates with early tau pathology |
| p-tau217 | Phosphorylated tau at Ser217 | High diagnostic accuracy for AD |
| p-tau231 | Phosphorylated tau at Ser231 | Detects early entorhinal involvement |
| MTBR-tau-243 | Tangle core fragments | Direct measure of NFT burden |
| Total tau | Neuronal injury | Non-specific neurodegeneration marker |
| NFL | Neurofilament light chain | Rate of axonal degeneration |
These biomarkers enable:
Alzheimer's disease is characterized by 3R/4R tau pathology with characteristic six-repeat isoform composition in PHFs[121]:
Progressive supranuclear palsy, corticobasal degeneration, and argyrophilic grain disease show 4R tau predominance[122]:
Pick's disease represents the prototype 3R tauopathy[123]:
Several frontiers promise to advance our understanding of tau spreading[124][125]:
Single-cell analysis: Single-nucleus RNA sequencing of tauopathic brains is revealing cell-type-specific transcriptional changes that influence vulnerability and propagation[126].
Cryo-EM structure: Continued cryo-electron microscopy studies are elucidating the atomic structures of tau filaments from different tauopathies, enabling strain-specific therapeutic approaches[127].
Mathematical modeling: Computational models of tau propagation are enabling prediction of disease progression and therapeutic response[128].
The recognition of tau strain diversity supports personalized therapeutic strategies[129][130]:
Tau spreading relates to:
Anti-tau therapeutics targeting tau spreading mechanisms:
| Agent | Company | Mechanism | Phase | Trial ID | Status |
|---|---|---|---|---|---|
| E2814 | Eisai | p-tau217, MTBR | Phase II/III | NCT05498661 | Recruiting |
| Bepranemab | UCB | p-tau231, MTBR | Phase II | NCT04134862 | Completed |
| Tilavonemab | Lilly | N-terminal | Phase II | NCT02460094 | Failed |
| Semorinemab | Roche | N-terminal | Phase II | NCT02880956 | Mixed |
| BIIB080 | Biogen | MAPT ASO | Phase II | NCT03053068 | Recruiting |
Hyman et al. 'The progression of neurodegeneration in Alzheimer''s disease: 2014'. 2014. ↩︎
Clavaguera et al. 'Prion-like propagation of mutant tau: 2009'. 2009. ↩︎
'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'. 2013. ↩︎
'Goedert, The ordered assembly of tau protein: 2015'. 2015. ↩︎
Frost et al. 'Crystalline aggregates of tau: 2009'. 2009. ↩︎
'Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991'. 1991. ↩︎
Goedert et al. 'Multiple isoforms of tau: 1988'. 1988. ↩︎
'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'. 2012. ↩︎
Baas et al. 'Tau and neurodegeneration: 2016'. 2016. ↩︎
'Ittner and Götz, Amyloid-β and tau—toxic partners: 2011'. 2011. ↩︎
Khlistunova et al. 'Inducible expression of tau: 2006'. 2006. ↩︎
'Goedert and Spillantini, Tau pathology in neurodegenerative diseases: 2000'. 2000. ↩︎
Ballatore et al. 'Tau hyperphosphorylation and neurodegeneration: 2007'. 2007. ↩︎
'Medina and Avila, Understanding tau phosphorylation: 2014'. 2014. ↩︎
Hanger et al. 'New perspectives on tau: 2009'. 2009. ↩︎
Gerson et al. 'Tau oligomers as therapeutic targets: 2016'. 2016. ↩︎
'Crowther, Straight and paired helical filaments: 1991'. 1991. ↩︎
'Mudher and Lovestone, Tau—does it have a role in neurodegeneration?: 2002'. 2002. ↩︎
Sawaya et al. 'The structures of amyloid protein: 2016'. 2016. ↩︎
Frost et al. 'Prion-like mechanisms in neurodegeneration: 2009'. 2009. ↩︎
'Jucker and Walker, Self-propagation of protein aggregates: 2013'. 2013. ↩︎
Wang et al. 'Exosomes in tau propagation: 2017'. 2017. ↩︎
Pooler et al. 'Activity-dependent tau release: 2013'. 2013. ↩︎
Lee et al. 'Unconventional secretion of tau: 2014'. 2014. ↩︎
Holmes et al. 'Heparan sulfate mediates tau uptake: 2013'. 2013. ↩︎
Sanders et al. 'Tau seeding: 2018'. 2018. ↩︎
Sanders et al. 'Tau strain diversity: 2014'. 2014. ↩︎
'Trojanowski and Lee, Axonal transport of tau: 2005'. 2005. ↩︎
Liu et al. 'Transsynaptic spread of tau: 2012'. 2012. ↩︎
Yamada et al. 'Activity-dependent release of tau: 2014'. 2014. ↩︎
Wu et al. 'Synaptic activity promotes tau release: 2016'. 2016. ↩︎
Sanders et al. 'Tau strains in different diseases: 2014'. 2014. ↩︎
Schubert et al. 'Tau strain variation: 2018'. 2018. ↩︎
Vogel et al. 'Tau strains in AD: 2020'. 2020. ↩︎
Neumann et al. 'CBD tau pathology: 2020'. 2020. ↩︎
Dickson et al. 'PSP tau pathology: 2012'. 2012. ↩︎
Ferrer et al. 'AGD tau pathology: 2008'. 2008. ↩︎
Fitzpatrick et al. 'Cryo-EM structures of tau filaments: 2017'. 2017. ↩︎
Shi et al. 'Tau structure and strain classification: 2021'. 2021. ↩︎
'Braak and Braak, Staging of Alzheimer-related pathology: 1991'. 1991. ↩︎
'Alzheimer''s Disease Neuroimaging Initiative, Tau staging: 2019'. 2019. ↩︎
Gómez-Isla et al. 'Neuronal loss and NFT formation: 1997'. 1997. ↩︎
Liu et al. 'Tau propagation along neural circuits: 2012'. 2012. ↩︎
Harris et al. 'Tau spread in neural networks: 2020'. 2020. ↩︎
Calafate et al. 'Synaptic tau spread: 2015'. 2015. ↩︎
Brettschneider et al. 'Spreading of pathology in neurodegenerative diseases: 2015'. 2015. ↩︎
Mandelkow et al. 'Tau and axonal transport: 2003'. 2003. ↩︎
Zhou et al. 'Network-based tau propagation: 2018'. 2018. ↩︎
'Seiler and Stoll, Tau spread through functional connectivity: 2021'. 2021. ↩︎
Gómez-Isla et al. 'Entorhinal cortex vulnerability: 1997'. 1997. ↩︎
Zhang et al. 'Glia in tau propagation: 2017'. 2017. ↩︎
Choi et al. 'Astrocyte uptake of tau: 2018'. 2018. ↩︎
Kovacs et al. 'Astrocytic tau pathology: 2016'. 2016. ↩︎
Asai et al. 'Microglia-mediated tau spread: 2015'. 2015. ↩︎
Maphis et al. 'Microglial activation and tau: 2015'. 2015. ↩︎
Ferrer et al. 'Oligodendrocyte tau pathology: 1999'. 1999. ↩︎
Brichta et al. 'Oligodendrocytes in tauopathy: 2013'. 2013. ↩︎
Saman et al. 'Exosomal tau in CSF: 2012'. 2012. ↩︎
Polanco et al. 'Exosomal tau seeding activity: 2018'. 2018. ↩︎
Pooler et al. 'Neuronal activity regulates tau secretion: 2013'. 2013. ↩︎
Yamada et al. 'Tau release from neurons: 2014'. 2014. ↩︎
Wu et al. 'Synaptic vesicle release of tau: 2016'. 2016. ↩︎
Meyer-Luehmann et al. 'NMDA receptor and tau: 2019'. 2019. ↩︎
Ittner et al. 'Excitotoxicity and tau: 2010'. 2010. ↩︎
Iaccarino et al. 'Gamma oscillations and tau: 2016'. 2016. ↩︎
'Nedergaard and Goldman, Glymphatic failure: 2020'. 2020. ↩︎
Lee et al. 'Tau secretion mechanisms: 2014'. 2014. ↩︎
Wang et al. 'Exosome biogenesis and tau: 2017'. 2017. ↩︎
Fader et al. 'Exosomal tau seeding: 2019'. 2019. ↩︎
Dujardin et al. 'Tau at the synapse: 2018'. 2018. ↩︎
Karch et al. 'Direct translocation of tau: 2012'. 2012. ↩︎
'Seiler and Stoll, Tau and functional connectivity: 2021'. 2021. ↩︎
Zhou et al. 'Network tau accumulation: 2018'. 2018. ↩︎
Palmqvist et al. 'Default mode network tau: 2017'. 2017. ↩︎
Buckner et al. 'Molecular architecture of the brain: 2009'. 2009. ↩︎
Jacobs et al. 'White matter and tau spread: 2018'. 2018. ↩︎
Boltze et al. 'Metabolic coupling and tau: 2019'. 2019. ↩︎
'Biase and Zuloaga, Therapeutic modulation of tau: 2019'. 2019. ↩︎
Medina et al. 'Tau-based therapeutics: 2018'. 2018. ↩︎
Koch et al. 'Brain stimulation and tau: 2021'. 2021. ↩︎
Brown et al. 'Exercise and tau: 2018'. 2018. ↩︎
Mironov et al. 'Tau propagation modifiers: 2019'. 2019. ↩︎
Holmes et al. 'Tau modifiers: 2014'. 2014. ↩︎
Baker et al. 'MAPT haplotype and risk: 2000'. 2000. ↩︎
Rademakers et al. 'MAPT in tauopathies: 2004'. 2004. ↩︎
Liu et al. 'APOE and tau propagation: 2017'. 2017. ↩︎
Goldberg et al. 'TBI and tau pathology: 2012'. 2012. ↩︎
Maphis et al. 'Neuroinflammation promotes tau spread: 2015'. 2015. ↩︎
Ahlskog et al. 'Exercise and neurodegenerative disease: 2008'. 2008. ↩︎
'Valcarcel-Ares and Gunn, Exercise benefits the brain: 2020'. 2020. ↩︎
Brown et al. 'Physical exercise and tau: 2018'. 2018. ↩︎
Moore et al. 'Exercise and tau clearance: 2020'. 2020. ↩︎
Xie et al. 'Sleep and glymphatic clearance: 2013'. 2013. ↩︎
Holmes et al. 'Tau-targeted drug development: 2014'. 2014. ↩︎
Davies et al. 'Tau therapeutics: 2016'. 2016. ↩︎
Himmler et al. 'Tau vaccination: 2020'. 2020. ↩︎
Boutajangout et al. 'Anti-tau antibodies: 2011'. 2011. ↩︎
Wischik et al. 'Tau aggregation inhibitors: 2015'. 2015. ↩︎
Gerson et al. 'Targeting tau oligomers: 2016'. 2016. ↩︎
Brunden et al. 'Tau kinase inhibitors: 2009'. 2009. ↩︎
DeVos et al. 'Antisense oligonucleotides for tau: 2017'. 2017. ↩︎
'Congdon and Sigurdsson, Tau-targeting therapies: 2018'. 2018. ↩︎
Huang et al. 'Clinical trials in tauopathy: 2020'. 2020. ↩︎
Schott et al. 'Tau biomarkers: 2022'. 2022. ↩︎
'Zetterberg and Bendlin, Biomarkers for tau: 2021'. 2021. ↩︎
Palmqvist et al. 'p-tau217 for early detection: 2020'. 2020. ↩︎
Janelidze et al. 'Blood p-tau for detection: 2020'. 2020. ↩︎
Saijo et al. 'Tau seeding assays: 2017'. 2017. ↩︎
'Goedert and Spillantini, Tau filaments in AD: 2017'. 2017. ↩︎
Dickson et al. '4R tauopathies: 2012'. 2012. ↩︎
'Lee and Leong, Future directions in tau research: 2020'. 2020. ↩︎
'Gandy and DeKosky, Toward tau-targeted therapy: 2019'. 2019. ↩︎
Mathys et al. 'Single-cell analysis of AD: 2019'. 2019. ↩︎
Falcon et al. 'Tau structures in disease: 2018'. 2018. ↩︎
'Vladimir and Bertsch, Tau propagation models: 2018'. 2018. ↩︎
'Jucker and Walker, Tau propagation in precision medicine: 2018'. 2018. ↩︎